HB Wealth Management LLC Has $417,000 Position in IQVIA Holdings Inc. $IQV

Key Points

• HB Wealth Management LLC reduced its holdings in IQVIA Holdings Inc. by 40.3% in the second quarter, now holding 2,644 shares valued at approximately $417,000.
• IQVIA reported a Q2 earnings per share of $2.81, exceeding analysts' expectations, and set FY 2025 guidance between 11.750-12.050 EPS.
• Analyst ratings have been favorable, with UBS Group raising its target price for IQVIA from $185.00 to $225.00 and maintaining a "buy" rating, alongside multiple other firms issuing high target prices.

HB Wealth Management LLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 40.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,644 shares of the medical research company's stock after selling 1,787 shares during the period. HB Wealth Management LLC's holdings in IQVIA were worth $417,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board lifted its position in shares of IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock worth $810,069,000 after buying an additional 312,807 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after acquiring an additional 798,534 shares during the period. American Century Companies Inc. grew its holdings in shares of IQVIA by 26.8% in the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock worth $253,695,000 after purchasing an additional 304,258 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of IQVIA by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock worth $251,852,000 after purchasing an additional 40,699 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in shares of IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock worth $153,681,000 after purchasing an additional 854,732 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Stock Up 1.2%

Shares of NYSE:IQV opened at $206.84 on Monday. The company has a 50 day moving average of $187.90 and a 200-day moving average of $167.44. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $237.34. The stock has a market cap of $35.16 billion, a price-to-earnings ratio of 29.93, a P/E/G ratio of 2.27 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on IQV shares. Cowen reaffirmed a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. UBS Group boosted their target price on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Truist Financial raised their price target on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Robert W. Baird boosted their price objective on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 target price on IQVIA in a report on Wednesday, September 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $230.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.